Pharmacoeconomics Evaluation of CYP2C19 Genetic Test Guiding Antiplatelet Therapy for Acute Coro-nary Syndrome Patients in China / 中国药房
China Pharmacy
; (12): 3183-3187, 2017.
Article
em Zh
| WPRIM
| ID: wpr-612260
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:To evaluate the feasibility of using CYP2C19 gene to guide the use of antiplatelet agents in acute cor-onary syndrome(ACS)patients undergoing interventional operation in China from the viewpoint of pharmacoeconomics. METH-ODS:Based on global PLATO trial data,the patients were divided into 3 groups according to treatment strategies(clopidogrel group,ticagrelor group,genetic test group). By applying Treeage Pro 2011 software,short-term decision tree model and long-term Markov model were established,and related data were imported to evaluate cost-effectiveness of different treatment strategies. RE-SULTS&CONCLUSIONS:For ACS patients,according to the level of GDP in China,conventional use of ticagrelor is of pharma-coeconomic advantage for in Shanghai and uninsured patients insured patients;the use of antiplatelet agents guided by CYP2C19 gene test is of pharmacoeconomic advantage among nationwide insured patients.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Idioma:
Zh
Revista:
China Pharmacy
Ano de publicação:
2017
Tipo de documento:
Article